Alkermes (ALKS) Expected to Announce Earnings on Thursday

Alkermes (NASDAQ:ALKS) is expected to issue its quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $0.80 per share and revenue of $379.74 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.Parties interested in registering for the company’s conference call can do so using this link.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. On average, analysts expect Alkermes to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Price Performance

Shares of NASDAQ ALKS opened at $33.50 on Thursday. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The stock has a market cap of $5.42 billion, a P/E ratio of 17.18, a P/E/G ratio of 1.83 and a beta of 0.49. The stock has a 50 day moving average of $30.16 and a two-hundred day moving average of $28.65. Alkermes has a twelve month low of $22.90 and a twelve month high of $33.73.

Analysts Set New Price Targets

A number of research firms recently weighed in on ALKS. HC Wainwright restated a “neutral” rating and issued a $37.00 price target on shares of Alkermes in a research note on Friday, October 25th. JPMorgan Chase & Co. reduced their price objective on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Cantor Fitzgerald lowered their target price on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Deutsche Bank Aktiengesellschaft started coverage on shares of Alkermes in a report on Tuesday. They issued a “buy” rating and a $40.00 target price for the company. Finally, The Goldman Sachs Group decreased their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $36.33.

Insider Activity

In other Alkermes news, EVP Craig C. Hopkinson sold 100,918 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total value of $3,234,421.90. Following the completion of the transaction, the executive vice president now owns 44,290 shares in the company, valued at $1,419,494.50. This represents a 69.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $31.85, for a total transaction of $85,708.35. Following the completion of the sale, the director now directly owns 23,013 shares of the company’s stock, valued at $732,964.05. This trade represents a 10.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 179,189 shares of company stock valued at $5,723,518 over the last quarter. Company insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.